Neuroinflammation is a common feature in the pathogenesis of Parkinson's disease (PD), together with - among others - oxidative stress, proteasomal and mitochondrial dysfunction. Peripheral inflammation-induced microglial activation has been shown to increase the susceptibility of the brain for nigrostriatal degeneration. The aim of this study is therefore to create a dual-hit mouse model for PD, characterized by lipopolysaccharide (LPS)-induced neuroinflammation prior to nigral proteasome inhibition. To do so, we administered repeated low-dose LPS injections (250µg/kg for 4 days; i.p.) or a single high-dose LPS injection (5mg/kg, i.p.), to induce neuroinflammation. Next, we administered a unilateral intranigral injection of lactacystin (LAC; 3µg), a proteasome inhibitor that acutely induces dopaminergic neurodegeneration. Seven days after administration of LAC, mice were evaluated behaviorally before collecting the brain. Nigrostriatal degeneration was analyzed by quantifying striatal dopamine loss as well as loss of nigral dopaminergic neurons. Presence of neuroinflammation was confirmed by labelling Iba1-positive cells in the substantia nigra (SN). Our results show that systemic LPS injection(s) induce(s) an increase in the number of Iba1-positive cells in the SN, without inducing degeneration of the nigrostriatal pathway. However, LPS-induced neuroinflammation increases the susceptibility for LAC-induced degeneration of the nigrostriatal pathway. This dual-hit model might as such represent a relevant mouse model for PD - combining two pathogenic mechanisms - to be used to investigate the potential of therapeutic targets.
Original languageEnglish
Title of host publicationFederation of European Neuroscience Society, 11th FENS Forum of Neuroscience, Berlin, 7-11 july 2018
Number of pages1
Publication statusPublished - 2018
Event11th FENS Forum of Neuroscience - Berlin, Germany
Duration: 7 Jul 201811 Jul 2018


Conference11th FENS Forum of Neuroscience

ID: 44032153